SAI LIFE SCIENCES LTD
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was … Read more
SAI LIFE SCIENCES LTD (SAILIFE) - Net Assets
Latest net assets as of September 2025: ₹22.70 Billion INR
Based on the latest financial reports, SAI LIFE SCIENCES LTD (SAILIFE) has net assets worth ₹22.70 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹33.32 Billion) and total liabilities (₹10.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹22.70 Billion |
| % of Total Assets | 68.13% |
| Annual Growth Rate | 34.3% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 53.3 |
SAI LIFE SCIENCES LTD - Net Assets Trend (2022–2025)
This chart illustrates how SAI LIFE SCIENCES LTD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SAI LIFE SCIENCES LTD (2022–2025)
The table below shows the annual net assets of SAI LIFE SCIENCES LTD from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹21.28 Billion | +118.26% |
| 2024-03-31 | ₹9.75 Billion | +9.80% |
| 2023-03-31 | ₹8.88 Billion | +1.08% |
| 2022-03-31 | ₹8.79 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to SAI LIFE SCIENCES LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 56.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹7.24 Billion | 34.04% |
| Common Stock | ₹208.41 Million | 0.98% |
| Other Comprehensive Income | ₹98.46 Million | 0.46% |
| Other Components | ₹13.73 Billion | 64.52% |
| Total Equity | ₹21.28 Billion | 100.00% |
SAI LIFE SCIENCES LTD Competitors by Market Cap
The table below lists competitors of SAI LIFE SCIENCES LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EVEREST MED.LTD DL-0001
F:6HN
|
$999.79 Million |
|
PT Pantai Indah Kapuk Dua Tbk
JK:PANI
|
$999.83 Million |
|
Suzhou Secote Precision Electronic Co Ltd Class A
SHG:603283
|
$1.00 Billion |
|
RF Capital Group Inc
PINK:GMPFF
|
$1.00 Billion |
|
Strathcona Resources Ltd.
PINK:STHRF
|
$999.67 Million |
|
American Assets Trust Inc
NYSE:AAT
|
$999.59 Million |
|
REalloys Inc.
NASDAQ:ALOY
|
$999.45 Million |
|
Robertet SA
PINK:RBTEF
|
$999.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SAI LIFE SCIENCES LTD's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,751,440,000 to 21,283,550,000, a change of 11,532,110,000 (118.3%).
- Net income of 1,701,320,000 contributed positively to equity growth.
- New share issuances of 10,116,420,000 increased equity.
- Other comprehensive income increased equity by 98,460,000.
- Other factors decreased equity by 384,090,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹1.70 Billion | +7.99% |
| Share Issuances | ₹10.12 Billion | +47.53% |
| Other Comprehensive Income | ₹98.46 Million | +0.46% |
| Other Changes | ₹-384.09 Million | -1.8% |
| Total Change | ₹- | 118.26% |
Book Value vs Market Value Analysis
This analysis compares SAI LIFE SCIENCES LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 23.12x to 9.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | ₹42.24 | ₹976.50 | x |
| 2023-03-31 | ₹42.70 | ₹976.50 | x |
| 2024-03-31 | ₹46.88 | ₹976.50 | x |
| 2025-03-31 | ₹107.71 | ₹976.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SAI LIFE SCIENCES LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.99%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.03%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.48x
- Recent ROE (7.99%) is above the historical average (4.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.71% | 0.72% | 0.40x | 2.46x | ₹-816.30 Million |
| 2023 | 1.12% | 0.83% | 0.55x | 2.46x | ₹-788.20 Million |
| 2024 | 8.49% | 5.69% | 0.64x | 2.33x | ₹-147.05 Million |
| 2025 | 7.99% | 10.03% | 0.54x | 1.48x | ₹-427.04 Million |
Industry Comparison
This section compares SAI LIFE SCIENCES LTD's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $7,618,434,558
- Average return on equity (ROE) among peers: 17.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SAI LIFE SCIENCES LTD (SAILIFE) | ₹22.70 Billion | 0.71% | 0.47x | $999.68 Million |
| Krsnaa Diagnostics Limited (KRSNAA) | $6.69 Billion | 10.23% | 0.31x | $122.87 Million |
| Dr. Lal Path Labs Ltd. (LALPATHLAB) | $1.17 Billion | 38.19% | 0.51x | $1.18 Billion |
| Metropolis Healthcare Limited (METROPOLIS) | $9.91 Billion | 14.42% | 0.52x | $551.52 Million |
| SURAKSHA (SURAKSHA) | $1.26 Billion | 5.10% | 0.36x | $28.12K |
| Syngene International Limited (SYNGENE) | $36.18 Billion | 12.84% | 0.61x | $854.33 Million |
| Thyrocare Technologies Limited (THYROCARE) | $1.02 Billion | 34.10% | 0.34x | $262.80 Million |
| Vijaya Diagnostic Centre Limited (VIJAYA) | $3.59 Billion | 23.52% | 0.51x | $538.66 Million |
| Vimta Labs Limited (VIMTALABS) | $1.12 Billion | 3.75% | 0.29x | $76.72 Million |